Dermapharm Holding SE
XETRA:DMP
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
30.15
42.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DMP stock under the Base Case scenario is 42.5 EUR. Compared to the current market price of 33.65 EUR, Dermapharm Holding SE is Undervalued by 21%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Dermapharm Holding SE
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DMP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Dermapharm Holding SE
Balance Sheet Decomposition
Dermapharm Holding SE
Current Assets | 695.1m |
Cash & Short-Term Investments | 171.7m |
Receivables | 113.2m |
Other Current Assets | 410.2m |
Non-Current Assets | 1.5B |
Long-Term Investments | 82.9m |
PP&E | 322.5m |
Intangibles | 1.1B |
Current Liabilities | 439.6m |
Accounts Payable | 93.2m |
Short-Term Debt | 24k |
Other Current Liabilities | 346.4m |
Non-Current Liabilities | 1.2B |
Long-Term Debt | 961.8m |
Other Non-Current Liabilities | 254.1m |
Earnings Waterfall
Dermapharm Holding SE
Revenue
|
1.1B
EUR
|
Cost of Revenue
|
-403.8m
EUR
|
Gross Profit
|
728m
EUR
|
Operating Expenses
|
-536.9m
EUR
|
Operating Income
|
191.1m
EUR
|
Other Expenses
|
-108.1m
EUR
|
Net Income
|
83m
EUR
|
Free Cash Flow Analysis
Dermapharm Holding SE
EUR | |
Free Cash Flow | EUR |
DMP Profitability Score
Profitability Due Diligence
Dermapharm Holding SE's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Dermapharm Holding SE's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
DMP Solvency Score
Solvency Due Diligence
Dermapharm Holding SE's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Dermapharm Holding SE's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DMP Price Targets Summary
Dermapharm Holding SE
According to Wall Street analysts, the average 1-year price target for DMP is 50.62 EUR with a low forecast of 41.92 EUR and a high forecast of 60.9 EUR.
Dividends
Current shareholder yield for DMP is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The company is headquartered in Gruenwald, Bayern and currently employs 2,373 full-time employees. The company went IPO on 2018-02-09. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Contact
IPO
Employees
Officers
The intrinsic value of one DMP stock under the Base Case scenario is 42.5 EUR.
Compared to the current market price of 33.65 EUR, Dermapharm Holding SE is Undervalued by 21%.